Related Experiment Video
Updated: Jul 10, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Management strategies for stage-D patients with acute heart failure
David Feldman1, Doron M Menachemi, William T Abraham
1Department of Physiology and Cell Biology, Ohio State University, Columbus, Ohio, USA. david.feldman@osumc.edu
Insights
Heart failure (HF) management involves aggressive pharmacologic treatments, medical devices, and surgical interventions. Guidelines recommend a combination of therapies for diverse patient needs, including advanced and refractory cases.
Area of Science:
- Cardiology
- Pharmacology
- Medical Devices
Background:
- Heart failure (HF) is a significant public health concern, evidenced by 3.4 million ambulatory visits in 2000.
- Current guidelines emphasize aggressive treatment strategies for HF patients.
Purpose of the Study:
- To outline current and emerging treatment modalities for heart failure.
- To provide an overview of pharmacologic, device-based, and surgical interventions.
Main Methods:
- Review of current guidelines from major cardiovascular societies.
- Summary of established and investigational therapeutic options.
Main Results:
- Pharmacologic interventions include diuretics, ACE inhibitors, beta-blockers, ARBs, aldosterone antagonists, digoxin, and nitrates/hydralazine.
- Medical devices such as LVADs, CRT, and ICDs are options for advanced HF.
- Heart transplantation and surgical ventricular restoration are considered for refractory cases.
Conclusions:
- A multi-faceted approach combining medications, devices, and surgery is crucial for managing heart failure.
- Treatment selection is tailored to patient severity, including acute decompensated and refractory HF stages.
Abstract:
Heart Failure (HF) accounted for 3.4 million ambulatory visits in 2000. Current guidelines from the American Heart Association/American College of Cardiology, the Heart Failure Society of America, and the International Society for Heart & Lung Transplantation recommend aggressive pharmacologic interventions for patients with HF. This may include a combination of diuretics, Angiotensin Converting Enzyme inhibitors, beta-blockers, angiotensin receptor blockers, aldosterone antagonists, and digoxin. Nitrates and hydralazine are also indicated as part of standard therapy in addition to beta-blockers and Angiotensin Converting Enzyme inhibitors, especially but not exclusively, for African Americans with left ventricular (LV) systolic dysfunction. For those with acute decompensated HF, additional treatment options include recombinant human B-type natriuretic peptide, and in the future possible newer agents not yet approved for use in the U.S., such as Levosimendan. Medical devices for use in patients with advanced HF include LV assist devices, cardiac resynchronization therapy, and implantable cardioverter defibrillators. For refractory patients, heart transplantation, the gold-standard surgical intervention for the treatment of refractory HF, may be considered. Newer surgical options such as surgical ventricular restoration may be considered in select patients.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure VI: Adjunct Therapies
Heart Failure VII: Nursing Interventions
Mitral Regurgitation IV: Nursing Management
Cardiomyopathy V: Interprofessional Care
